Natera, Inc. - NTRA STOCK NEWS

Natera, Inc. (NASDAQ: NTRA) has announced significant findings from the CIRCULATE-Japan trial concerning its Signatera test for colorectal cancer (CRC). The study involved over 3,000 CRC patients, with key results presented at the ASCO GI 2022 conference. Notably, MRD-positive patients saw substantial benefits from adjuvant chemotherapy, while MRD-negative patients did not. The study also highlighted a 67.6% sensitivity of the Signatera test in detecting cancer recurrences. These results may influence future treatment guidelines for CRC.

Natera, Inc. (NASDAQ: NTRA) announced the publication of the groundbreaking SMART study in the American Journal of Obstetrics and Gynecology, demonstrating the efficacy of its non-invasive prenatal testing (NIPT) for detecting 22q11.2 deletion syndrome (22q11.2DS). Enrolling over 20,000 patients globally, the study reveals a prevalence of 1 in 1,524 pregnancies, with Panorama detecting all common cases and achieving a low false positive rate of 0.05%. This supports the expansion of routine prenatal screening to include 22q11.2DS, emphasizing the need for diagnostic follow-ups.

Natera, Inc. (NASDAQ: NTRA) announced new data presentations at the ASCO GI Symposium from January 20-22, 2022, concerning its tumor-informed molecular residual disease test, Signatera. Highlighted studies include two oral presentations and four posters focusing on colorectal, pancreatic, and anal cancers. One study shows how MRD testing can predict treatment benefits for colorectal cancer patients post-surgery. An investor call reviewing the ASCO GI results is scheduled for January 24, 2022, at 1:30 PM PT.

Natera, Inc. (NASDAQ: NTRA) has announced the appointment of Dr. Alexey Aleshin as General Manager of Early Cancer Detection (ECD), part of its strategic expansion into the ECD market. Dr. Aleshin, who has extensive experience in oncology, will continue overseeing medical affairs while leading ECD initiatives. The company aims to leverage a biobank of colorectal cancer samples from Aarhus University, potentially accelerating ECD product development and FDA approval. CEO Steve Chapman emphasizes the opportunity to improve early cancer detection, enhancing patient outcomes.

Austin, Texas-based Natera, a leader in personalized genetic testing, announced a live presentation at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. PT. CEO Steve Chapman and CFO Mike Brophy will discuss recent business activities and Natera's growth plans in the genetic testing industry. The presentation will address its impact on critical health decisions. Interested parties can access the live webcast and the archived presentation on investor.natera.com.

Natera, Inc. (NASDAQ: NTRA) presented key findings at the 2021 San Antonio Breast Cancer Symposium highlighting the use of its Signatera test in high-risk breast cancer patients. The studies indicated that detecting circulating tumor DNA (ctDNA) both pre- and post-surgery was crucial in predicting disease relapse, with ctDNA status being the strongest predictor of patient outcomes. As a custom-built test for monitoring cancer treatment, Signatera has shown significant potential in clinical settings for improving patient care and optimizing treatment strategies.

Natera, Inc. (NASDAQ: NTRA) announced the acceptance of the first manuscript from its groundbreaking SMART study for publication in the American Journal of Obstetrics and Gynecology. This study validates the Panorama non-invasive prenatal test (NIPT) for common trisomies, confirming its 99% sensitivity and >99.5% specificity for trisomy 21. The SMART study, involving over 20,000 patients, utilized an advanced AI algorithm, Panorama AI, which lowered the no-call rate to 1.5%. This research enhances the confidence of physicians in screening for genetic disorders during pregnancy.

Natera announced that the CMS has issued a final local coverage determination for pan-cancer immunotherapy monitoring using its Signatera molecular residual disease test. This coverage applies to Medicare patients undergoing immunotherapy, significantly expanding access to personalized monitoring. The Signatera test has shown high predictive accuracy in identifying non-responders early in treatment, aiming to improve cancer care outcomes. Natera sees this development as a crucial step in enhancing treatment decisions across various tumor types.